Goodin Burel R, Anderson Austen J B, Freeman Emily L, Bulls Hailey W, Robbins Meredith T, Ness Timothy J
Departments of Psychology.
Anesthesiology, University of Alabama at Birmingham.
Clin J Pain. 2015 Sep;31(9):757-767. doi: 10.1097/AJP.0000000000000166.
This study examined whether the administration of intranasal oxytocin was associated with pain sensitivity, endogenous pain inhibitory capacity, and negative mood states.
A total of 30 pain-free, young adults each completed 3 laboratory sessions on consecutive days. The first session (baseline) assessed ischemic pain sensitivity, endogenous pain inhibition via conditioned pain modulation (CPM), and negative mood using the Profile of Mood States. CPM was tested on the dominant forearm and ipsilateral masseter muscle using algometry (test stimulus) and the cold pressor task (conditioning stimulus; nondominant hand). For the second and third sessions, participants initially completed the State-Trait Anxiety Inventory and then self-administered a single (40 IU/1 mL) dose of intranasal oxytocin or placebo in a randomized counterbalanced order. Thirty minutes postadministration, participants again completed the State-Trait Anxiety Inventory and repeated assessments of ischemic pain sensitivity and CPM followed by the Profile of Mood States.
Findings demonstrated that ischemic pain sensitivity did not significantly differ across the 3 study sessions. CPM at the masseter, but not the forearm, was significantly greater following administration of oxytocin compared to placebo. Negative mood was also significantly lower following administration of oxytocin compared to placebo. Similarly, anxiety significantly decreased following administration of oxytocin but not placebo.
This study incorporated a placebo-controlled, double-blind, within-subjects crossover design with randomized administration of intranasal oxytocin and placebo. The data suggest that the administration of intranasal oxytocin may augment endogenous pain inhibitory capacity and reduce negative mood states including anxiety.
本研究旨在探讨鼻内注射催产素是否与疼痛敏感性、内源性疼痛抑制能力及负面情绪状态相关。
共有30名无疼痛的年轻成年人连续3天每天完成3次实验室测试。第一次测试（基线）使用情绪状态量表评估缺血性疼痛敏感性、通过条件性疼痛调制（CPM）评估内源性疼痛抑制以及负面情绪。使用压力测定法（测试刺激）和冷加压任务（条件刺激；非优势手）在优势前臂和同侧咬肌上测试CPM。在第二次和第三次测试中，参与者首先完成状态-特质焦虑量表，然后以随机平衡的顺序自行注射单剂量（40 IU/1 mL）的鼻内催产素或安慰剂。给药30分钟后，参与者再次完成状态-特质焦虑量表，并重复评估缺血性疼痛敏感性和CPM，随后进行情绪状态量表评估。
研究结果表明，在3次研究测试中，缺血性疼痛敏感性无显著差异。与安慰剂相比，注射催产素后咬肌（而非前臂）的CPM显著增强。与安慰剂相比，注射催产素后负面情绪也显著降低。同样，注射催产素后焦虑显著降低，而注射安慰剂后则无此现象。
本研究采用了安慰剂对照、双盲、受试者内交叉设计，随机给予鼻内催产素和安慰剂。数据表明，鼻内注射催产素可能增强内源性疼痛抑制能力，并减少包括焦虑在内的负面情绪状态。
